|
|
|
|
|
|
|
12.08.25 - 14:03
|
Eureka Therapeutics Appoints Dr. Reginald Seeto and William S. Solari III to Board of Directors (Business Wire)
|
|
|
EMERYVILLE, Calif.--(BUSINESS WIRE)--Eureka Therapeutics, Inc., a clinical-stage biotechnology company pioneering safer and more effective T-cell therapies, today announced the appointment of Dr. Reginald Seeto and William S. Solari III to its Board of Directors.
Dr. Seeto is a global leader in biopharmaceuticals and diagnostics with expertise in corporate strategy, business development, and operations. He currently serves as President and CEO of Scipher Medicine. Previously, he was President and CEO of CareDx, Inc., guiding the company through a period of rapid growth. He served as Chief Operating Officer at Ardelyx, where he built international partnerships to support commercialization, and held senior leadership roles at AstraZeneca, where he completed over 100 biologics transactions and managed portfolio strategy for more than 150 assets. His earlier career includes McKinsey & Company, Boehringer Ingelheim, and Organon.
Mr. Solari brings over 30 years of legal and financial experience in corporate gov...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
05.08.25 - 13:36
|
Organon Reports Results for the Second Quarter Ended June 30, 2025 (Business Wire)
|
|
|
Second quarter 2025 revenue of $1.594 billion
Second quarter 2025 diluted earnings per share of $0.56 and non-GAAP Adjusted diluted earnings per share of $1.00; GAAP diluted earnings per share includes a $46 million gain, or $0.14 per share, for early extinguishment of debt
Second quarter 2025 net income of $145 million and Adjusted EBITDA (non-GAAP) of $522 million, representing an Adjusted EBITDA margin of 32.7%
The company repaid $345 million of long-term debt during the quarter; on track to achieve a net debt to Adjusted EBITDA ratio of less than 4.0x by year-end
Revenue guidance range for full year 2025 raised to $6.275 billion to $6.375 billion based on the company's current views of foreign exchange; guidance range for Adjusted EBITDA margin (non-GAAP) affirmed at 31.0% to 32.0%
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN) today announced its results for the second quarter ended June 30, 2025.
“During the quarter we paid down principal on our long-term debt and began implementing mean...
|
|
|
|
|
|
|
|
|
|
|
|
|
22.07.25 - 13:33
|
Organon To Report Second Quarter 2025 Results and Host Conference Call on August 5, 2025 (Business Wire)
|
|
|
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a primary focus on women's health, will release its second quarter 2025 financial results on August 5, 2025, prior to the company's webcast and conference call scheduled for 8:30 a.m. EDT.
Accessing Second Quarter 2025 Financial Results Webcast
Interested parties may access the live call via webcast on the Organon website at https://www.organon.com/investor-relations/events-and-presentations/. A replay of the webcast will be available approximately two hours after the conclusion of the live event on the company's website.
Institutional investors and analysts interested in participating in the call may join by dialing (888) 596-4144 (U.S. and Canada Toll-Free) or (646) 968-2525 and using the access code Conference ID: 1036555#.
About Organon
Organon (NYSE: OGN) is a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. With a portfolio of over 70 products a...
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
